BR112019002331A2 - anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos - Google Patents

anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos

Info

Publication number
BR112019002331A2
BR112019002331A2 BR112019002331A BR112019002331A BR112019002331A2 BR 112019002331 A2 BR112019002331 A2 BR 112019002331A2 BR 112019002331 A BR112019002331 A BR 112019002331A BR 112019002331 A BR112019002331 A BR 112019002331A BR 112019002331 A2 BR112019002331 A2 BR 112019002331A2
Authority
BR
Brazil
Prior art keywords
siglec
antibodies
obtaining
methods
cancer treatment
Prior art date
Application number
BR112019002331A
Other languages
English (en)
Inventor
Bebbington Christopher
Luehrsen Kenneth
Tomasevic Nenad
El Bader Susy
Korver Wouter
Original Assignee
Allakos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allakos Inc filed Critical Allakos Inc
Publication of BR112019002331A2 publication Critical patent/BR112019002331A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

a invenção provê métodos e composições para o tratamento de câncer usando anticorpos anti-siglec-7.
BR112019002331A 2016-08-05 2017-08-04 anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos BR112019002331A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662371680P 2016-08-05 2016-08-05
PCT/US2017/045641 WO2018027203A1 (en) 2016-08-05 2017-08-04 Anti-siglec-7 antibodies for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112019002331A2 true BR112019002331A2 (pt) 2019-06-18

Family

ID=61073084

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019002331A BR112019002331A2 (pt) 2016-08-05 2017-08-04 anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos

Country Status (13)

Country Link
US (1) US11773162B2 (pt)
EP (1) EP3494142A4 (pt)
JP (1) JP7137563B2 (pt)
KR (1) KR20190035863A (pt)
CN (1) CN109790223A (pt)
AU (1) AU2017307616A1 (pt)
BR (1) BR112019002331A2 (pt)
CA (1) CA3032437A1 (pt)
EA (1) EA201990296A1 (pt)
IL (1) IL264674B2 (pt)
MX (1) MX2019001471A (pt)
SG (1) SG11201901020RA (pt)
WO (1) WO2018027203A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN109790223A (zh) 2016-08-05 2019-05-21 阿拉科斯有限责任公司 用于治疗癌症的抗siglec-7抗体
KR102376863B1 (ko) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. 메소텔린 결합 단백질
EP3652207A1 (en) * 2017-07-10 2020-05-20 Innate Pharma Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancer
CA3087968A1 (en) 2018-01-11 2019-07-18 Allakos, Inc. Anti-siglec-7 antibodies having reduced effector function
JP7425049B2 (ja) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． Ｄｌｌ３結合タンパク質および使用方法
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
WO2007120815A2 (en) * 2006-04-12 2007-10-25 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
EP2172483A4 (en) * 2007-07-04 2010-08-04 Forerunner Pharma Res Co Ltd ANTI-MUC17 ANTIBODY
DK2817338T3 (en) 2012-02-24 2017-10-23 Abbvie Stemcentrx Llc DLL3 modulators and methods of use
DK2934584T3 (da) * 2012-12-21 2020-05-18 Aveo Pharmaceuticals Inc Anti-gdf15-antistoffer
US20160115231A1 (en) * 2013-05-21 2016-04-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Treatment of mast cell related pathologies
JP6125110B2 (ja) 2014-08-07 2017-05-10 第一三共株式会社 抗Ｏｒａｉ１抗体
CA2957351A1 (en) * 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies
CA2996059A1 (en) * 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
WO2017123745A1 (en) * 2016-01-12 2017-07-20 Palleon Pharma Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
EP3426688A1 (en) * 2016-03-08 2019-01-16 Innate Pharma Siglec neutralizing antibodies
CN109790223A (zh) 2016-08-05 2019-05-21 阿拉科斯有限责任公司 用于治疗癌症的抗siglec-7抗体

Also Published As

Publication number Publication date
JP2019526622A (ja) 2019-09-19
EA201990296A1 (ru) 2019-08-30
SG11201901020RA (en) 2019-03-28
WO2018027203A1 (en) 2018-02-08
MX2019001471A (es) 2019-10-30
KR20190035863A (ko) 2019-04-03
CN109790223A (zh) 2019-05-21
EP3494142A4 (en) 2020-04-01
IL264674B1 (en) 2023-05-01
EP3494142A1 (en) 2019-06-12
JP7137563B2 (ja) 2022-09-14
IL264674B2 (en) 2023-09-01
IL264674A (pt) 2019-03-31
CA3032437A1 (en) 2018-02-08
US11773162B2 (en) 2023-10-03
US20190194323A1 (en) 2019-06-27
AU2017307616A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
ZA202107931B (en) Anti-tau antibodies and methods of use
CY1120373T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
EA201800444A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CR20190271A (es) Anticuerpos antitau y métodos de uso
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
BR112017000130A2 (pt) método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2019006330A (es) Anticuerpos anti-tau y metodos de uso.
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
EA201991818A1 (ru) Лечение рака
CY1124123T1 (el) Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου
CY1123019T1 (el) Σπειροκυκλικες ενωσεις
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EA201790529A1 (ru) Новые антитела против mfi2 и способы их применения
MX2020006297A (es) Variantes de cd19.
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
BR112018005331A2 (pt) inibidores de pcna

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]